Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenqi Yanshen is a Traditional Chinese Medicine (TCM) herbal formula, typically prepared as a granule, developed by the Chongqing Traditional Chinese Medicine Hospital. It is primarily indicated for the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). The formulation is based on the TCM principle that the "kidney governs bone and generates marrow," and it is studied for its ability to regulate bone turnover markers and inhibit osteoclast differentiation. By addressing the systemic mineral imbalances and bone metabolism issues associated with chronic renal failure, Shenqi Yanshen aims to improve clinical outcomes in patients with CKD-MBD.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shenqi Yanshen.